FDA warned Hims & Hers (Hers) that its website misleads consumers about compounded semaglutide by implying it is the same as approved Ozempic and Wegovy.
What happened
FDA reviewed the website forhers.com in August 2025 and found it offering compounded drug products, including semaglutide. FDA said two claims on the site — that the weekly injectable GLP-1 has "the same active ingredient as Ozempic and Wegovy" and that it uses "clinically proven ingredients" — falsely suggest the products are the same as FDA-approved drugs. Because compounded drugs are not FDA-approved, FDA calls the products misbranded (labeled or promoted in a false or misleading way).
What FDA found
The website's claims about compounded semaglutide are false or misleading, which makes the drug misbranded.
Section 502(a) of the FDCA [21 U.S.C. § 352(a)]Advertising or promotion for a compounded drug that is false or misleading makes that drug misbranded.
Section 502(bb) of the FDCA [21 U.S.C. § 352(bb)]The claims imply the compounded products are the same as FDA-approved products when they are not.
Sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a), 352(bb)]Shipping these misbranded drugs across state lines is a prohibited act.
Section 301(a) of the FDCA [21 U.S.C. § 331(a)]Receiving misbranded drugs in interstate commerce, or delivering them, is also prohibited.
Section 301(c) of the FDCA [21 U.S.C. § 331(c)]
What FDA wants
FDA tells the company to take immediate action, including stopping use of the cited claims, and to send a written response within 15 working days describing the steps taken and how it will prevent repeat violations.
Who should pay attention
- telehealth companies selling compounded GLP-1 drugs
- compounding pharmacies that supply such telehealth sellers
- marketing and compliance teams that write prescription drug website claims
This is a summary. Read the original letter on fda.gov.